Replies to post #70 on Somaxon Pharmaceuticals, Inc. (SOMX)

[dylyo]

no official resubmission and it is up on very little volume

once they actually re-submit the process is 90 days I believe for FDA review


so you have 90 days to deal with ups and downs - how ever the market wants to react

I am planning on rolling my OSCI profits into this one for a new buyin